ArticleFrontiers in medicine2026
Long-term effectiveness and safety of vedolizumab in ulcerative colitis: a real-world retrospective cohort study over 2 years.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vedolizumab (VDZ), a gut-selective anti-integrin therapy, has demonstrated efficacy in ulcerative colitis (UC) clinical trials, but real-world long-term data from Asia, particularly from Chinese populations, remain limited. Therefore, this study aimed to evaluate the long-term effectiveness and safety of vedolizumab in Chinese patients with UC in a real-world setting over a 2-year period. Methods: In this retrospective cohort study conducted at a tertiary hospital in China, patients aged ≥18 years old who received VDZ for UC between December 2020 and August 2023 were enrolled. Information on the clinical characteristics, prior/concomitant treatment, and safety during the observation period was collected. Results: The data obtained from 112 patients (males, Conclusion: This real-world study confirms vedolizumab's sustained effectiveness in UC, with durable remission and excellent safety over 2 years. The findings support its position in treatment algorithms and highlight the value of early response assessment in guiding therapeutic decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.